FOXO1 and Hyperglycemia: Metformin-activated AMPK directly hinders hyperglycemia-stimulated nuclear translocation of ChREBP and forkhead box O1 (FOXO1), preventing their subsequent recruitment on TxNIP promoter (Li et al, 2015).